ArticleMucosal immunology2017
Sphingosine-1-phosphate receptor-1 (S1P
Open access · bronzeAbstract read
In one paragraph
Article in Mucosal immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 116 citations in OpenAlex.
- Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data.Journal of Crohn's & colitis · 2026Trial
- Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?Nutrients · 2020Trial
- Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.Journal of clinical pharmacology · 2017Trial
- Aberrant sphingosine-1-phosphate receptor 1 expression on activated naive B cells associated with disease activity and lupus nephritis in systemic lupus erythematosus.Arthritis research & therapy · 2026Article
- The sphingosine-1-phosphate pathway is differentially activated in human gestational tissues.Journal of the Endocrine Society · 2026Article
- Small-molecule therapies for pediatric inflammatory bowel disease: toward precision medicine.World journal of pediatrics : WJP · 2026Review
- Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Metabolic regulation of gut barrier integrity in IBD: protein, lipid, and carbohydrate pathways.Frontiers in nutrition · 2026Review
- Engineering Peptide Modulators for T-Cell Migration by Structural Scaffold Matching.Journal of medicinal chemistry · 2025Article
- Biotin/sulfasalazine combination therapy alleviates acetic acid-induced ulcerative colitis in rats via modulation of S1PR1/NF-κB/IL-23/STAT3/COX-2 axis.Scientific reports · 2025Article
- S1P Lyase Inhibition Increased Intestinal S1P, Disrupted the Intestinal Barrier and Aggravated DSS-Induced Colitis.Inflammatory bowel diseases · 2025Article
- Review
- Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis.Journal of clinical medicine · 2025Review
- Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis.BMJ open gastroenterology · 2025Article
- Intestinal microbiota regulates naïve lymphocyte migration in Peyer's patches.Frontiers in immunology · 2025Article
- Efficacy and safety of sphingosine-1-phosphate receptor modulators in the management of inflammatory bowel disease: a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2025Review
- Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management.Drugs · 2024Review
- Design, synthesis, and biological evaluation of multiple F-18 S1PR1 radiotracers in rodent and nonhuman primate.Organic & biomolecular chemistry · 2024Article
- Myeloid Cells and Sphingosine-1-Phosphate Are Required for TCRαβ Intraepithelial Lymphocyte Recruitment to the Colon Epithelium.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
T KaruppuchamyDivision of Gastroenterology, Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA.
E-H BehrensDivision of Gastroenterology, Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA.
P González-CabreraDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, California, USA.
G SarkisyanDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, California, USA.
L GimaDivision of Gastroenterology, Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA.
J D BoyerDivision of Gastroenterology, Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA.
G BamiasAcademic Department of Gastroenterology, Laikon Hospital, Athens, Greece.
P JedlickaDepartment of Pathology, University of Colorado Health Sciences, Aurora, Colorado, USA.
M VenyDivision of Gastroenterology, Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA.
D ClarkDivision of Gastroenterology, Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA.
R PeachReceptos Inc., La Jolla, California, USA.
F ScottReceptos Inc., La Jolla, California, USA.
H RosenDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, California, USA.
J Rivera-NievesDivision of Gastroenterology, Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA.
University of California San Diego · USScripps Research Institute · USLaiko General Hospital of Athens · GRUniversity of Colorado Health · US
Funding
Novel Traffic-targeted Therapies for IBDR01DK108670 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RIVERA-NIEVES, JESUS · 2016 to 2020
$3.3MDendritic Cell Manipulation: A Novel Therapeutic for Inflammatory Bowel DiseaseI01BX001051 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI RIVERA-NIEVES, JESUS · 2011 to 2015
–BLRD VA I01 BX001051NIDDK NIH HHS R01 DK108670
Abstract
The sphingosine-1-phosphate receptor-1 (S1P
Indexed as
AnimalsCell MovementCells, CulturedColitisDendritic CellsDextran SulfateDisease Models, AnimalEndotheliumFingolimod HydrochlorideHumansImmunologic FactorsImmunologic MemoryIndansInflammatory Bowel DiseasesIntestinesLymphocytesDextran SulfateFingolimod HydrochlorideImmunologic FactorsIndansOxadiazolesozanimodReceptors, Lysosphingolipid
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.